Exogenous human recombinant interleukin-10 protects the kidney against hypoxia-induced renal injury in immature rats.
OBJECTIVE
The purpose of this study was to determine the effects of exogenous human recombinant interleukin-10 (rhIL-10) on hypoxia-induced renal injury in immature rats.


METHODS
The study was performed on 1-day-old Sprague-Dawley rat pups. Group 1 (n = 8) served as non-hypoxic controls. Group 2 (untreated, n = 8) rats were subjected to hypoxia-reoxygenation (H/O) and were then returned to their mothers. Group 3 (rhIL-10 treated, n = 8) rats were subjected to H/O, were returned to their mothers, and were treated with rhIL-10 (75 microg/kg subcutaneously) for the next 3 days. All animals were killed on day 4 and renal specimens were obtained to determine the tissue level of malondialdehyde (MDA) and histological changes.


RESULTS
In the untreated group, moderate or severe renal tubular necrosis was observed However, the tubular necrosis score was significantly less in the rhIL-10 treated rats than in the untreated rats (P < 0.05). In the untreated group, MDA levels were significantly increased compared with the control and rhIL-10 groups (P < 0.001 and P < 0.05, respectively). In the rhIL-10 treated group, MDA levels were not significantly different compared with the control group.


CONCLUSIONS
RhIL-10 has a protective effect against hypoxia-induced renal injury in immature rats by depression of tissue MDA level and renal tubular necrosis score.
Oztürk
Hayrettin
H
Department of Pediatric Surgery, Dicle University, Medical School, Diyarbakir, Turkey. ozturkhayrettin@hotmail.com
Onen
Abdurrahman
A
Oztürk
Hulya
H
Buyukbayram
Huseyin
H
D000818:Animals; D000831:Animals, Newborn; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000150:complications* / Q000473:pathology; D016753:Interleukin-10 / Q000627:therapeutic use*; D007511:Ischemia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007668:Kidney / Q000098:blood supply*; D007684:Kidney Tubules / Q000473:pathology; D008315:Malondialdehyde / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D016753:Interleukin-10; D008315:Malondialdehyde